Michael S. Gordon - 25 Jul 2025 Form 4/A - Amendment Insider Report for ProMIS Neurosciences Inc. (PMN)

Role
Other*
Signature
/s/ Michael S. Gordon
Issuer symbol
PMN
Transactions as of
25 Jul 2025
Net transactions value
$0
Form type
4/A - Amendment
Filing time
14 Aug 2025, 16:17:09 UTC
Date Of Original Report
29 Jul 2025
Previous filing
02 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
GORDON MICHAEL S Other* C/O TROVE,, 40 BROAD STREET, 8TH FLOOR, BOSTON /s/ Michael S. Gordon 14 Aug 2025 0001034608

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PMN Tranche A Common Share Purchase Warrants Exercise of in-the-money or at-the-money derivative security $0 -119,800 -26% $0.000000 345,316 25 Jul 2025 Common Shares 119,800 See footnote F1, F2, F3
transaction PMN Tranche B Common Share Purchase Warrants Exercise of in-the-money or at-the-money derivative security $0 -119,800 -26% $0.000000 345,316 25 Jul 2025 Common Shares 119,800 See footnote F2, F3, F4
transaction PMN Tranche C Common Share Purchase Warrants Exercise of in-the-money or at-the-money derivative security $0 -119,800 -26% $0.000000 345,316 25 Jul 2025 Common Shares 119,800 See footnote F2, F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310.
F2 This amendment is being filed to report that the price at which the Tranche A purchase warrants, Tranche B purchase warrants and Tranche C purchase warrants were exercised was inadvertently disclosed as $0.83158 instead of $0.83518.
F3 By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager.
F4 On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310.
F5 On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029.

Remarks:

The Issuer's Form 10-Q filed on August 13, 2025 provides that as of such date, the Issuer had 51,806,497 Common Shares outstanding. Based on this number and other shares included in the denominator of the calculation of the Reporting Person's ownership, the Reporting Person's ownership has dropped below 10% as of the date of filing this amended Form 4. However, based on the publicly available number of outstanding shares reported prior to when this Form 4 was originally filed, the Reporting Person held more than 10% at such time the Form 4 was originally filed.